INTRODUCTION {#s1}
============

Bladder cancer (BC) is the second most common urological malignancy in the United States. In 2015, approximately 73,510 new cases of BC were diagnosed and 14,680 individuals died of this disease in the U.S. \[[@R1]\]. In South Korea, BC is the second most common genitourinary tumor and the incidence of BC is about five times greater in men than it is in women \[[@R2]\].

Conventional diagnosis of BC classifies the tumor into two groups based on its clinico-pathologic features: non-muscle invasive (NMIBC) and muscle-invasive (MIBC). \[[@R3]\]. At the time of first diagnosis, a majority of cases are classified as NMIBC. However, approximately 20% of BC is confirmed as MIBC *in situ*, which is the main cause of cancer-specific deaths in BC patients. In general, NMIBC has a much better prognosis than MIBC and survival rates for NMIBC are higher than those for other malignancies. However, even after transurethral resection (TUR) of the primary tumor, the chance of recurrence is common with NMIBC. Approximately 30-50% of patients with NMIBC experience recurrence in their lifetime. NMIBC also runs the risk of possibly progressing into MIBC but the chances are usually low, ∼10-20% \[[@R4], [@R5]\]. Therefore, frequent recurrence and eventual progression to MIBC are challenges for both patients and urologists. Despite technical improvements in the diagnosis of BC, more efficient diagnostic tests that can facilitate early diagnosis and active surveillance are urgently needed. We currently lack an ideal non-invasive detection tool and there is a need for more accurate and predictive biomarkers.

To date, more than 1,100 microRNAs (miRNAs) have been identified in the human genome, far fewer than the total number of mRNAs. However, rather than being strictly one to one, interactions between miRNAs and target genes can be one-to-many or many-to-one, resulting in a very large number of potential regulatory effects. In addition, there is some controversy regarding the specific mode of how miRNA acts \[[@R6]\]. Several studies have shown that miRNAs repress mRNAs by regulating their stability or translation efficiency. Regarding BC, evidence from expression profiling studies using microarray-based approaches has provided abundant information to support the theory of miRNAs. Nevertheless, data about the interactions between miRNAs and mRNAs is inconsistent, and little is known about their expression levels and physiologically relevant functions in cancer cells.

In this study, we sought to identify NMIBC- or MIBC-specific miRNAs, predict their associated genes and miRNA-mRNA interactions based on bioinformatics analyses and validation by next-generation sequencing (NGS), and determine the critical networks and pathways that are dysregulated in BC patients. Our results provide important insight into the mechanisms underlying NMIBC and MIBC in human patients, as well as BC progression.

RESULTS {#s2}
=======

Identification of differentially expressed genes between BC tissue and normal tissue {#s2_1}
------------------------------------------------------------------------------------

Determination of mRNAs was performed as shown in Figure [1](#F1){ref-type="fig"}. We extracted 522 genes that were differentially expressed in NMIBC versus normal tissue, 105 genes differentially expressed in MIBC versus normal tissue, and 60 genes differentially expressed in NMIBC versus MIBC. All genes were then validated by RNA sequencing from a second cohort. A Venn diagram shows that 402/522 genes in NMIBC and 33/105 genes in MIBC were exclusively dysregulated compared to that of normal tissue, and 11/60 genes were differentially expressed only between NMIBC and MIBC (Figure [2A](#F2){ref-type="fig"}). To understand the biological functions of these genes, we subjected each of them to network enrichment analysis using GeneMANIA and STRING. The 402/522 differentially expressed genes in the NMIBC were strongly associated with the extracellular matrix (ECM) (false discovery rate (FDR), 1.35E-17) and extracellular structure organization (FDR, 2.98E-13) ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}). The 33/105 differentially expressed genes in the MIBC were associated with mitosis (FDR, 1.72E-21) and nuclear division (FDR, 1.88E-20) ([Supplementary Table 2](#SD1){ref-type="supplementary-material"}). The 11/60 genes that were differentially expressed between NMIBC and MIBC were associated with cellular responses to zinc ions (FDR, 4.12E-11) ([Supplementary Table 3](#SD1){ref-type="supplementary-material"}). Seventy-two genes, whose functions are related to nuclear division and G2/M transition in cell mitosis, showed different expression between BC and normal tissues.

![Schematic showing negatively correlated gene-miRNA pairs in NMIBC and MIBC\
Differentially expressed mRNAs and miRNAs were identified according to -fold changes in expression and *p*-value criteria. MiRNA-targeted gene pairs were identified using miRNAs and mRNAs differentially expressed in NMIBC and MIBC versus normal tissue according to previously validated informations regarding mRNA-miRNA interactions. NMIBC, non-muscle invasive bladder cancer; MIBC, muscle invasive bladder cancer.](oncotarget-09-27656-g001){#F1}

![Venn diagram showing mRNAs and miRNAs differentially expressed in BC\
**(A)** mRNA expression. **(B)** miRNA expression. BC, bladder cancer; NMIBC, non-muscle invasive bladder cancer; MIBC, muscle invasive bladder cancer.](oncotarget-09-27656-g002){#F2}

Identification of miRNAs differentially expressed between BC tissue and normal tissue {#s2_2}
-------------------------------------------------------------------------------------

MiRNAs were determined as shown in Figure [1](#F1){ref-type="fig"}. We extracted 70 miRNAs differentially expressed in NMIBC versus normal tissue, 25 miRNAs differentially expressed in MIBC versus normal tissue, and 6 miRNAs differentially expressed in NMIBC versus MIBC, all of which were validated by RNA sequencing in a second cohort. The Venn diagram shows that 58 miRNAs were exclusively deregulated in NMIBC versus normal, 17 were specifically deregulated in MIBC versus normal, and 2 miRNAs were differentially expressed only between NMIBC and MIBC (Figure [2B](#F2){ref-type="fig"}). By comparing our data with 190 miRNAs identified in a previously reported miRNA profiling study of BC \[[@R7]\], we identified 27 novel miRNAs: miR-124, miR-1260a, miR-136, miR-149, miR-191, miR-301b, miR-302a, miR-302c, miR-3065, miR-3195, miR-331, miR-335, miR-34a, miR-363, miR-371a, miR-381, miR-409, miR-4284, miR-4492, miR-4532, miR-4634, miR-483, miR-484, miR-5581, miR-5701, miR-590, and miR-654.

NMIBC-/MIBC-specific gene-miRNA interactions {#s2_3}
--------------------------------------------

Next, we attempted to identify gene-miRNA interactions based on the validated mRNAs and miRNAs specific for NMIBC and MIBC. This analysis proceeded by two steps: first, we identified candidate gene target miRNAs based on experimentally validated datasets from the mirTarBase v6 \[[@R8]\] in miRWalk 2.0 \[[@R9]\]. Through this, we obtained 8,542 gene-miRNA interaction pairs for the 522 NMIBC genes derived from the mRNA expression profiles (NMIBC vs normal) and 1,740 gene-miRNA interaction pairs for the 105 MIBC genes (MIBC vs. normal). Next, among the gene-miRNA interaction pairs, only significantly expressed genes and miRNAs that paired with each other were selected to further analyze for differences between normal versus NMIBC and normal versus MIBC. Finally, we obtained 227 genes that paired with 54 miRNAs in NMIBC (Figure [3](#F3){ref-type="fig"}, [Supplementary Table 4](#SD2){ref-type="supplementary-material"}), and 14 genes that paired with 10 miRNAs in MIBC (Figure [3](#F3){ref-type="fig"}, [Supplementary Table 5](#SD1){ref-type="supplementary-material"}). These miRNAs were compared with190 previously reported miRNAs \[[@R10]\]. This enabled us to identify 14 novel miRNAs: seven (miR-1260a, miR-149, miR-191, miR-335, miR-34a, miR-484, and miR-5701) in NMIBC and seven (miR-124, miR-302c, miR-331, miR-371a, miR-4492, miR-4634, and miR-483) in MIBC (Table [1](#T1){ref-type="table"}). To validate biological replication on miRNA-mRNA interacted genes, we were recruited and reanalysis GSE and the cancer genome atlas (TCGA) data with AnaltAnlyzer \[[@R11]\]. Finally, these 14 miRNAs showed negative correlations with 130 genes from differentially expressed analysis that were validated expression in NMIBC using GSE40355. The seven miRNAs showed negative correlations with 10 genes from differentially expressed analysis that were validated its expression in MIBC using GSE40355 \[[@R12]\], GSE66064 \[[@R13]\] and RNA sequences from TCGA (Table [1](#T1){ref-type="table"}).

![Venn diagram showing paired gene and miRNA in BC\
**(A)** Genes associated with gene-miRNA interactions. **(B)** miRNAs associated with gene-miRNA interactions. BC, bladder cancer; NMIBC, non-muscle invasive bladder cancer; MIBC, muscle invasive bladder cancer.](oncotarget-09-27656-g003){#F3}

###### Expression profiling of miRNA-mRNA interacted target genes in NMIBC and MIBC

  a\. Normal versus NMIBC                                                                                                                    
  ------------------------- ------ -------- ----------- ------ --------- ---------- -------- --------- ------ --------- ---- -------- ------ ------
  miR-1260a                 Up     RNF150   Down        NA     miR-335   Up         ATP8B2   Down      NA     miR-335   Up   AKAP12   Down   Down
  PRNP                      Down   Down     CCL19       Down   Down      CD1D       Down     Down                                            
  miR-149                   Up     CALD1    Down        Down   CD14      Down       Down     CD37      Down   Down                           
  FLNA                      Down   Down     CD8A        Down   Down      CDKN1C     Down     Down                                            
  GFPT2                     Down   Down     CFI         Down   Down      COL21A1    Down     Down                                            
  JUN                       Down   Down     CGNL1       Down   Down      DLG2       Down     Down                                            
  NFIX                      Down   NA       COL3A1      Down   Down      F10        Down     Down                                            
  NR2F1                     Down   Down     CYGB        Down   NA        GNA14      Down     NA                                              
  miR-191                   Up     EGR1     Down        Down   CYTL1     Down       Down     GPR162    Down   NA                             
  miR-335                   Up     ABCA8    Down        Down   CYYR1     Down       Down     GZMK      Down   NA                             
  ADAMTS8                   Down   Down     DACT1       Down   Down      ITPR1      Down     Down                                            
  ANTXR2                    Down   Down     DNASE1L3    Down   Down      KLRB1      Down     Down                                            
  AOC3                      Down   Down     DOCK11      Down   NA        MAFB       Down     Down                                            
  BIN1                      Down   NA       FBLN5       Down   NA        MFGE8      Down     Down                                            
  C1S                       Down   Down     FILIP1L     Down   Down      MXRA8      Down     Down                                            
  CDH11                     Down   NA       FZD1        Down   NA        NAALAD2    Down     Down                                            
  CLIC4                     Down   Down     FZD10       Down   Down      NFIL3      Down     Down                                            
  COLEC12                   Down   NA       GABARAPL1   Down   Down      RECK       Down     Down                                            
  COL6A1                    Down   Down     GATA5       Down   NA        RERG       Down     Down                                            
  CPE                       Down   Down     GSN         Down   Down      TLR1       Down     NA                                              
  CRISPLD2                  Down   Down     HCST        Down   Down      VNN2       Down     Down                                            
  DACH1                     Down   Down     ITGB2       Down   Down      miR-34a    Up       AXIN2     Down   Down                           
  FBLN2                     Down   NA       KIAA1644    Down   Down      AXL        Down     Down                                            
  FGL2                      Down   NA       LIFR        Down   Down      BCL2       Down     Down                                            
  FHL1                      Down   Down     LMOD1       Down   Down      CALD1      Down     Down                                            
  FOS                       Down   NA       NKG7        Down   Down      CSF1R      Down     Down                                            
  GNA14                     Down   NA       OTUD1       Down   Down      EPB41L2    Down     Down                                            
  HLA-DRB5                  Down   Down     P2RX1       Down   Down      GAS1       Down     Down                                            
  KLF9                      Down   Down     PLSCR4      Down   Down      MAP1B      Down     Down                                            
  LMO3                      Down   Down     PODN        Down   NA        RTN4       Down     NA                                              
  LPPR4                     Down   Down     PPAP2B      Down   Down      TGFBR2     Down     Up                                              
  LTBP4                     Down   Down     PRICKLE2    Down   Down      TGM2       Down     Up                                              
  MAOB                      Down   Down     PROS1       Down   Down      TPM1       Down     Down                                            
  MGP                       Down   NA       RARRES2     Down   NA        VASN       Down     NA                                              
  NFIB                      Down   Down     RASD1       Down   NA        ZEB2       Down     NA                                              
  OLFML3                    Down   Down     RHOB        Down   Down      miR-484    Up       ACTA2     Down   Down                           
  PDE5A                     Down   NA       RORB        Down   NA        ATP1A2     Down     Down                                            
  PDK4                      Down   Down     SCARA5      Down   Down      CRTAP      Down     Down                                            
  RNASE4                    Down   Down     SCRG1       Down   NA        DSTN       Down     NA                                              
  RNF150                    Down   NA       SFRP1       Down   Down      FAM129A    Down     NA                                              
  ROR2                      Down   Down     SLC46A2     Down   Down      FLNA       Down     Down                                            
  SERPINF1                  Down   Down     SORBS2      Down   Down      KLF2       Down     Down                                            
  SERPING1                  Down   Down     TNC         Down   NA        TSC22D3    Down     Down                                            
  SMOC2                     Down   Down     TNC         Down   NA        TUBB2A     Down     Up                                              
  SYNPO2                    Down   Down     TSC22D3     Down   Down      miR-5701   Up       RUNX1T1   Down   Down                           
  TGFBR2                    Down   Up       VASN        Down   NA                                                                            
  ZFP36L1                   Down   Down     ZEB2        Down   NA                                                                            

  b\. Normal versus MIBC                                                                                               
  ------------------------ ------ ------- ------ ------ ---------- ------ ---------- ------ ------- ------ ------ ---- ----
  miR-124                  Down   EZH2    Up     NA     NA         Up     miR-371a   Down   MCM10   Up     Up     Up   Up
  KIF2C                    Up     NA      Up     Up     MELK       Up     Up         NA     Up                         
  AURKA                    Up     Up      NA     Up     miR-4492   Down   CDCA8      Up     Up      Up     Up          
  KIF20A                   Up     NA      NA     Up     miR-4634   Down   POLQ       Up     Up      NA     Up          
  miR-302c                 Down   MELK    Up     Up     NA         Up     miR-483    Up     FGF9    Down   Down   NA   NA
  miR-331                  Up     NELL2   Down   Down   NA         NA                                                  

NA: Not available

NMIBC, non-muscle invasive bladder cancer; MIBC, muscle invasive bladder cancer.

To understand the biological functions of the genes that interacted with miRNAs, selected genes were subjected to network enrichment analysis using GeneMANIA and STRING. We found that 221 genes differentially expressed in NMIBC were strongly associated with the ECM (FDR, 4.60E-18) and extracellular structure organization (FDR, 1.72E-11). ([Supplementary Table 6](#SD1){ref-type="supplementary-material"}), whereas 8 differentially expressed genes in MIBC were involved in spindle formation (FDR, 7.53E-15) and mitosis (FDR, 2.80E-10) ([Supplementary Table 7](#SD1){ref-type="supplementary-material"}).

The influence of transcription factors (TFs) on BC tumorigenesis {#s2_4}
----------------------------------------------------------------

In addition to miRNAs, gene expression is also regulated by TF**s**. Therefore, we decided to investigate the relationship between TFs and miRNA-interaction genes using the transcriptional regulatory element database (TRED). Twenty-two genes (ACTA2, BCL2, C1S, CAV1, CD14, COL3A1, COL6A1, CTGF, ESR1, F3, FOS, GJA1, ITGB2, JUN, MGP, PRNP, TGFBI, TPM2, TYMS, UCHL1, VIM, and ZFP36L1) are regulated by 62 TF**s** in 36 TF families \[[@R14]\]. Most target genes of TFs were down-regulated in BC; an exception was the thymidylate synthetase (TYMS) gene, which is regulated by E2F4, MYC, TP53, USF1, and USF2 regulatory elements (Table [2](#T2){ref-type="table"}).

###### A lot of TFs interacted with target genes in this study

  Transcription factor   Expression   Target genes   Expression   Transcription factor   Expression   Target genes   Expression   Transcription factor   Expression   Target genes   Expression
  ---------------------- ------------ -------------- ------------ ---------------------- ------------ -------------- ------------ ---------------------- ------------ -------------- ------------
  ELK1                   Up           ACTA2          Down         PPARG                  Up           ESR1           Down         HIF1A                  Up           ITGB2          Down
  ATF1                   Up           BCL2           Down         RARA                   Up           Down           SPI1         Up                     Down                        
  BRCA1                  Up           Down           SMAD4        Up                     Down         ATF1           Up           JUN                    Down                        
  CEBPA                  Up           Down           SP1          Up                     Down         ATF2           Up           Down                                               
  CREB1                  Up           Down           SP3          Down                   Down         BCL6           Up           Down                                               
  EGR1                   Down         Down           TFAP2C       Up                     Down         CREB1          Up           Down                                               
  ETS1                   Up           Down           USF1         Up                     Down         CREM           Up           Down                                               
  MYB                    Up           Down           AR           Up                     F3           Down           EGR1         Down                   Down                        
  MYC                    Up           Down           CEBPA        Up                     Down         ERG            Up           Down                                               
  NFKB1                  Up           Down           CEBPB        Up                     Down         ESR1           Down         Down                                               
  NFKB2                  Up           Down           CEBPD        Up                     Down         ESR2           Up           Down                                               
  PPARG                  Up           Down           CREB1        Up                     Down         ETS2           Up           Down                                               
  RARA                   Up           Down           E2F4         Up                     Down         JUN            Down         Down                                               
  RARB                   Down         Down           EGR1         Down                   Down         MYC            Up           Down                                               
  RARG                   Up           Down           HIF1A        Up                     Down         NFIC           Up           Down                                               
  RELA                   Up           Down           JUN          Down                   Down         PGR            Up           Down                                               
  STAT1                  Up           Down           JUND         Up                     Down         RARA           Up           Down                                               
  STAT3                  Up           Down           MYB          Up                     Down         RARB           Down         Down                                               
  WT1                    Up           Down           NFIC         Up                     Down         RARG           Up           Down                                               
  E2F1                   Up           C1S            Down         NFKB1                  Up           Down           REL          Up                     Down                        
  E2F2                   Up+          CAV1           Down         REL                    Up           Down           SMAD3        Up                     Down                        
  E2F4                   Up           Down           RELA         Up                     Down         SMAD4          Up           Down                                               
  ESR1                   Down         CD14           Down         SP3                    Down         FOS            Down         SP1                    Up           Down           
  SP1                    Up           Down           TFAP2A       Up+                    Down         STAT1          Up           Down                                               
  CEBPA                  Up           Down           ARNT         Up                     Down         STAT3          Up           Down                                               
  CEBPB                  Up           Down           ATF1         Up                     Down         JUN            Down         MGP                    Down                        
  RELB                   Up           Down           ATF2         Up                     Down         AR             Up           PRNP                   Down                        
  SP1                    Up           Down           BCL6         Up                     Down         E2F4           Up           Down                                               
  SP2                    Up           Down           CEBPB        Up                     Down         JUN            Down         Down                                               
  SP3                    Down         Down           CREB1        Up                     Down         TFAP2A         Up+          Down                                               
  JUN                    Down         COL3A1         Down         CREM                   Up           Down           SMAD1        Up                     TGFBI        Down           
  NFIC                   Up           Down           ESR1         Down                   Down         MYC            Up           TPM2                   Down                        
  SMAD1                  Up           Down           ESR2         Up                     Down         E2F4           Up           TYMS                   Up                          
  SMAD3                  Up           Down           ETS1         Up                     Down         MYC            Up           Up                                                 
  AR                     Up           COL6A1         Down         ETS2                   Up           Down           USF1         Up                     Up                          
  SMAD3                  Up           Down           ETV4         Up+                    Down         USF2           Up           Up                                                 
  TFAP2A                 Up           Down           FLI1         Up                     Down         MYB            Up           UCHL1                  Down                        
  SP1                    Up           CTGF           Down         JUN                    Down         Down           MYC          Up                     Down                        
  WT1                    Up           Down           NFIC         Up                     Down         ERG            Up           VIM                    Down                        
  AR                     Up           ESR1           Down         NFKB1                  Up           Down           ETV4         Up                     Down                        
  BRCA1                  Up           Down           STAT1        Up                     Down         LEF1           Up           Down                                               
  BRCA2                  Up           Down           STAT3        Up                     Down         MYB            Up           Down                                               
  ERG                    Up           Down           JUN          Down                   GJA1         Down           NFKB1        Up                     Down                        
  HIF1A                  Up           Down           SP1          Up                     Down         SP1            Up           Down                                               
  JUN                    Down         Down           CEBPA        Up                     ITGB2        Down           MYC          Up                     ZFP36L1      Down           
  PAX5                   Up           Down           CEBPB        Up                     Down                                                                                        

TF, transcription factor; BC, bladder cancer

DISCUSSION {#s3}
==========

In this study, we used two different methods to identify global miRNA-mRNA interactions and their enriched functional networks that are specific to NMIBC and MIBC. Microarrays were used to obtain differential expression profiles, while RNA-Seq was used for experimental validation of both miRNA and mRNA levels. Additionally, those gene expression pattern were validated using another cohort which were previously reported GSE and TCGA \[[@R11]--[@R13]\]. These results showed that expression pattern of gene-miRNA interacted genes were conserved in NMIBC and MIBC on tumorigenesis. We uncovered detailed patterns of miRNA and gene expression, allowing us to propose molecular markers for specific subtypes of BC. The 402 genes differentially expressed in NMIBC were related to ECM function, platelet activation, and multicellular organismal metabolism. Moreover, we found that the miRNAs interacted with the 221 genes in NMIBC were mainly related to the ECM, organization of extracellular structure, and muscle contraction. In contrast, the 33 genes differentially expressed in MIBC were mainly related to mitosis, antigen processing and presentation via MHC class II, and G2/M transition. In addition, we found that 8 miRNA-interaction genes in MIBC were related to spindle formation, mitosis, and nuclear division.

The results of gene-network analysis of gene-miRNA pairs revealed that ADAMTS8, COL21A1, COL3A1, COL6A1, COL6A2, COL18A1, FBLN2, FBLN5, F3, LTBP4, MFGE8, MGP, PARRES2, SERPINF1, SFRP1, SNCA, TGFBI, TGFB3, TNC, and VEGFA genes, which were down-regulated in NMIBC, are involved in the formation or function of the ECM, including the release of new growth factors and ECM molecules. The ECM serves as a structural scaffold that provides the support necessary to maintain tissue integrity and sustainability \[[@R15]\]. Therefore, ECM regulation is important for the generation of new tissue structures, as well as maintaining the architecture and homeostasis of adult tissues \[[@R15]\]. In addition to our discovery of a potential panel of genes for BC, the genes we found that modulate smooth muscular contraction (ACTA2, ATP1A2, CALD1, CAV1, EDNRA, GJA1, LMOD1, MYH11, MYLK, TPM1, TPM2, and VIM) could represent potential therapeutic targets for the treatment of diseases related to bladder contraction \[[@R15]\].

Cell cycle-related genes (AURKA, CDCA8, KIF20A, and KIF2C) were overexpressed in MIBC compared to NMIBC. Moreover, genes that play a role in cell cycle division are over-expressed in BC when compared with normal tissues. Therefore, since cell division, chromatin replication, and chromosome segregation are key targets for drug development, miRNA-targeted genes involved in nuclear division and G2/M transition may be candidate targets for drugs designed to treat BC \[[@R16]\].

Previously published studies propose 440 up- or down-regulated miRNAs as BC biomarkers, which comprise 190 union miRNAs. Among them, miR-145 was down-regulated in multiple different types of cancer tissue, helping to maintain the differentiation status of smooth muscle cells. This observation was reported consistently by 11 other groups \[[@R7]\], suggesting that miR-145 is likely to be a critical factor in BC tumorigenesis. Finally, our comprehensive analyses identified 14 novel miRNAs specific to BC (miR-124, miR-1260a, miR-149, miR-191, miR-302c, miR-331, miR-335, miR-34a, miR-371a, miR-4492, miR-4634, miR-483, miR-484, and miR-5701).

Members of the miR-183 cluster are located within a 5 kb region on human chromosome 7q32.2, and are transcribed in the same direction (from telomere to centromere) \[[@R17]\]. Previous studies have shown that the miR-183 cluster was abnormally expressed in a variety of tumors and could be directly involved in human cancers \[[@R18]\]. Notably, miR-183-3p, miR-182-5p, and miR-96-5p have oncogenic functions in BC \[[@R19], [@R20]\], and we found here that these miRNAs were over-expressed in both NMIBC and MIBC. In particular, the miR-183 cluster regulates genes that overlap in both NMIBC and MIBC, i.e., DKK3 (a target of miR-183-5p), FGF9 (a target of miR-182-5p), and monooxygenase, DBH-Like 1 (MOXD1, a target of miR-96-5p), suggesting that these miRNAs play important roles in bladder tumorigenesis. Our present study is also one of the first to reveal that MOXD1 is regulated by miR-96-5p in BC tissue. MOXD1 encodes a member of the copper monooxygenase/dopamine/β-hydroxylase family, which is localized to the endoplasmic reticulum. Members of this protein family are mainly involved in biosynthesis of neurotransmitters and hormones.

Furthermore, several lines of evidence indicate that miR-200b and miR-200c are over-expressed to a greater extent in NMIBC than in MIBC, consistent with previous studies \[[@R21]\]. The miR-200 family is thought to play an essential role in tumor suppression by inhibiting the epithelial-mesenchymal transition (EMT), an initiating step of metastasis \[[@R22]\]; because cells lose adhesion during the EMT, the rate of cell mortality is elevated during this process. In particular, miR-200 promotes the final step of metastasis in which migrating cancer cells undergo EMT during colonization of distant tissues \[[@R23]\]. Interestingly, our data shows that miR-200b and miR-200c were more highly expressed in NMIBC than in MIBC. Moreover, our study is the first to report the BCL2 (a target of miR-200b-3p and miR-200c-3p), CDH11 (a target of miR-200c-3p), FBLN5 (a target of miR-200c-3p), and TIMP2 (a target of miR-200c-3p) interaction pairs in NMIBC ([Supplementary Table 4a](#SD2){ref-type="supplementary-material"}).

Through analysis of the gene-miRNA pairs after linking the expression profiles of TFs and miRNAs to their target genes, we found that the expression of almost all TFs was moderately or severely repressed while miRNAs were over-expressed in BC tissues versus normal tissues. The exceptions to this general trend were E2F2, TFAP2A, and ETV4; TFs that were over-expressed in BC tissue. These results suggest that these TFs and miRNAs may regulate target genes with oncogenic properties in BC tumorigenesis. While almost all of the target genes in the gene-miRNA pairs showed lower expression, the TYMS gene interestingly showed over-expression, indicating possible oncogenic properties. This suggests that miR-99a-5p, which interacts with TYMS, and TFs E2F4, MYC, USF1, and USF2 regulate the expression of the TYMS gene. Further work is needed to gain a better understanding of how TFs and miRNAs act as both oncogenes and tumor suppressors. Advancements could potentially lead to the development of therapeutic targets from the expression profiling data of TFs, miRNAs, and the target genes in BC.

In summary, our validated data obtained from NGS-based experiments, combined with comprehensive and unbiased computational analyses of published data, identified 14 novel miRNAs in BC. Furthermore, genes differentially expressed in NMIBC were associated with the ECM, muscle contraction, and nuclear division. Gene enrichment analysis of the gene-miRNA pairs also suggest that the organization of the ECM is important in NMIBC, whereas DNA replication and G2/M transition are important in MIBC. This report provides the first evidence for novel gene-miRNA interaction pairs involving 227 genes and 54 miRNAs in NMIBC and 14 genes and 10 miRNAs in MIBC.

The promising findings from this study may lead to potentially novel diagnostic and therapeutic interventions in BC and other cancers.

MATERIALS AND METHODS {#s4}
=====================

Patients {#s4_1}
--------

The study cohort included 234 patients histologically diagnosed with bladder urothelial carcinoma and 83 individuals without BC. Tumor levels were assessed according to standard criteria \[[@R3]\]. The BC samples were further subcategorized into two groups, NMIBC and MIBC. NMIBC patients, who were usually treated with TUR, were periodically assessed by cystoscopy and urinary cytology every 3 months for the first 2 years, every 6 months for the next 3 years, and annually thereafter. Patients with MIBC underwent radical cystectomy and complete pelvic lymph node dissection. These patients were also subjected to urinary diversion, including creation of a conduit, continent cutaneous reservoir, and orthotopic ileal neobladder. Moreover, MIBC patients with pT3/pT4/lymph node--positive disease were subjected to four to six cycles of cisplatin-based adjuvant chemotherapy. These MIBC patients were subjected to physical examination, urine cytology, serum chemistry, chest x-ray, and abdominal and pelvic computerized tomography every 3 months for the first 2 years, every 6 months for the following 2 years, and then annually thereafter. Clinical data was assessed for all patients retrospectively. The mean follow-up of these patients was 71 months (median 61 months; range, 15--115 months). Normal muscosae was collected far from tumors and real normal mucosae from benign diseases. All specimens were rapidly frozen in liquid nitrogen and stored at -80°C until use. Collection and analysis of samples was approved by the Institutional Review Board of Chungbuk National University (IRB approval number 2006-01-001 and GR2010-12-010), and informed consent was obtained from each subject.

Datasets {#s4_2}
--------

High-throughput molecular datasets were generated for miRNAs using two different technologies. Microarray and RNA sequencing mRNA data were generated by RNA sequencing. The analysis also included microarray datasets published previously by our group (Gene Expression Omnibus accession number GSE13507) \[[@R24]\]. Sample sizes are provided in Figure [1](#F1){ref-type="fig"}.

Library preparation and data generation {#s4_3}
---------------------------------------

### RNA extraction {#s4_3_1}

Total RNA was isolated from the indicated tissues using the TRIzol reagent (Life Technologies, Carlsbad, CA) and purification was performed using phenol based extraction methods according to the manufacturer's instructions. The RNA concentration was determined using NanoDrop ND-1000 spectrometer and the RNA integrity number was evaluated on a 2100 Bioanalyzer (Agilent, Santa Clara, CA) using the RNA 6000 Nano Kit (Agilent, Santa Clara, CA).

### miRNA microarrays {#s4_3_2}

Total RNA (100 ng) from each sample was dephosphorylated, 3\' end--labeled with Cy3-pCp, purified on Micro Bio-Spin columns, dried, and hybridized using the miRNA Microarray System labeling kit ( Illumina, San Diego, CA) and the Agilent Human miRNA Microarray Release 16.0 platform, which contains 1,205 human and 144 viral miRNAs \[[@R25]\]. The protocol used to generate microarray gene expression datasets is provided in reference \[[@R26]\].

### Stranded mRNA library construction {#s4_3_3}

mRNA sequencing libraries were prepared using the TruSeq Stranded mRNA Sample Preparation Kit (RS-122-2101) (Illumina, San Diego, CA). Oligo dT attached magnetic beads were used to purify poly-A--containing mRNA from 1 μg of total RNA. Next, the purified mRNA was disrupted into short fragments, and first-strand cDNAs were synthesized using SuperScript II reverse transcriptase (Invitrogen, Carlsbad, CA) and random hexamers. cDNA with adapters ligated to both ends were enriched by PCR. cDNA library size and quality were evaluated electrophoretically using the Agilent DNA 1000 Kit (part \# 5067-1504) on a 2100 BioAnalyzer. Subsequently, the libraries were sequenced on an Illumina HiSeq 2500. Image analysis was performed using the HiSeq control software version 2.2.58. Raw data were processed and base calling was performed using the standard Illumina pipeline (CASAVA version 1.8.2 and RTA version 1.18.64).

### Small RNA library construction {#s4_3_4}

Small RNA sequencing libraries were constructed using the TruSeq Small RNA Sample Preparation protocol (RS-200-0012) (Illumina, San Diego, CA). Illumina adapters were directly and specifically ligated to microRNA molecules with a 3\'-hydroxyl group and a 5\'-phosphate. The quality and size distribution of the adapter-ligated RNAs and amplified libraries were confirmed using the High Sensitivity DNA Analysis Kit (Cat. \#5067-4626) (Agilent, Santa Clara, CA). Libraries were quantitated using the Library Quantification Kit for NGS (KK4824) (Kapa Biosystems, Wilmington, MA). Subsequently, libraries were sequenced on an Illumina HiSeq 2500. Real-time image analysis and base calling were performed on the instrument using the HiSeq Sequencing Control Software version 2.2.58. CASAVA software version 1.8.2 and RTA version 1.18.64 were used for de-multiplexing and generation of FASTQ sequence files.

Data analysis {#s4_4}
-------------

### Microarrays {#s4_4_1}

The Robust Multiarray Average, in the R package \[[@R27]\], was used to perform global correction, quantile normalization, and median Polish summarization. *P*-values (t test) were calculated from bead mRNA signal intensities \[[@R27]\].

### mRNA sequencing {#s4_4_2}

Total sequencing reads were subjected to preprocessing as follows: adapter trimming was performed using cutadapt with default parameters, and quality trimming (Q30) was performed using FastQC with default parameters. Processed reads were mapped to the human reference genome (Ensembl 72 \[GRCh37: hg19\]) using tophat and cufflink with default parameters \[[@R28]\]. Fragments Per Kilobase of exon per million fragments Mapped (FPKM) values were normalized and quantitated using R package Tag Count Comparison (TCC) \[[@R29]\] to determine statistical significance (e.g., P and Q values) and differential expression (e.g., -fold changes).

### miRNA sequencing {#s4_4_3}

Total sequencing reads were subjected to preprocessing: adapter trimming, quality trimming, size selection (17--24 nt), and clustering using mirDeep2 with default parameters \[[@R30]\]. The preprocessed cluster representatives were mapped to the human reference genome (Ensembl 72 \[GRCh37; hg19\]), and miRNA regions were mined with respect to miRBase reference co-ordinates. Total read counts were subjected to Trimmed mean m-values normalization and quantitation using R package edgeR, and statistical significance (e.g., P and Q values) and differential expression (e.g. -fold changes) were determined.

### Integrated analysis of differentially expressed miRNAs and mRNAs {#s4_4_4}

For data obtained using each technology, we used different cut-offs to identify differentially expressed mRNAs and miRNAs. Initially, thresholds for p-values (*P* ≤ 0.05) and -fold changes (log~2~FC ≥ 1.0) were applied to the microarray dataset. Thresholds for the RNA-sequencing datasets were as follows: mRNAs (FPKM ≥ 0.3, *P* ≤ 0.05, FDR ≤ 0.05, and log~2~FC ≥ 1.0) and miRNAs (read count ≥ 10, *P* ≤ 0.05, FDR ≤ 0.05, and log~2~FC ≥ 1.0). Finally, mRNAs common to the microarray dataset and mRNA-Seq datasets were selected as validated mRNAs. MiRNAs common to the microarray dataset and miRNA-Seq datasets were selected as validated miRNAs. The selected mRNAs and miRNAs were paired using validated target datasets and according to inverse expression relationships (i.e., miRNAs whose level increased as that of their target decreased and *vice versa*).

### Analysis of the relation between transcription factors (TFs) and miRNA-interacting genes {#s4_4_5}

TRED was used to identify the TFs related to the miRNA targeting genes in BC. There are curated 36 cancer-related TF families in TRED \[[@R14]\]. And we compared the miRNA-mRNA interacted pairs with the known TF families.

### Pathway enrichment analysis {#s4_4_6}

Pathway enrichment analysis was performed by submitting selected miRNAs to DIANA mirPath V3.0 \[[@R31]\]. Significantly correlated and enriched pathways were identified by calculating significant p-values using Fisher's meta-analysis method for specific miRNAs. Finally, the list of genes was examined using GeneMANIA \[[@R32]\] to identify interactive functional networks from existing databases.

SUPPLEMENTARY MATERIALS TABLES {#s5}
==============================
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MIBC

:   Muscle invasive bladder cancer
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:   microRNA
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TCGA

:   The cancer genome atlas
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TRED

:   Transcriptional regulatory element database
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